

# Teriflunomide

---

## Selected References:

- Almas S, et al. 2016. Management of multiple sclerosis in the breastfeeding mother. *Mult Scler Int*:6527458.
- Amato MP and Portaccio E. 2015. Fertility, Pregnancy and Childbirth in Patients with Multiple Sclerosis: Impact of Disease-Modifying Drugs. *CNS Drugs* 29:207-220.
- Andersen JB, et al. 2018. Pregnancy outcomes in men and women treated with teriflunomide. A population-based nationwide Danish registry study. *Frontiers in Immunology* 9(2706):1-7.
- Aubagio® Prescribing Information. 12/2022. Available online at <http://products.sanofi.us/aubagio/aubagio.pdf>, accessed 12/2022.
- Barataud-Reilhac A, et al. 2020. Teriflunomide-exposed pregnancies in French cohort of patients with multiple sclerosis. *Neurol Clin Pract* 10(4): 287-297.
- Cree BA. 2013. Update on reproductive safety of current and emerging disease-modifying therapies for multiple sclerosis. *Mult Scler*.19:835-43.
- Chambers CD, et al. 2010. Birth outcomes in pregnant women taking leflunomide. *Arthritis Rheu*. 62(5):1494-503.
- Chambers C, et al. 2007. Are new agents used to treat rheumatoid arthritis safe to take during pregnancy? Organization of Teratology Information Specialists (OTIS) study. *Motherisk Update*. 53(3):409-412.
- Cassina M, et al. 2012. Pregnancy outcome in women exposed to Leflunomide before or during pregnancy. *Arth & Rheum* 64(7):2085-2094.
- D'Aleo G, et al. 2020. Twin pregnancy outcome following teriflunomide treatment in a relapsing-remitting multiple sclerosis patient: A case report. *Medicine (Baltimore)* 99(28):e21212.
- Davenport L, et al. 2014. Teriflunomide: non-clinical evaluation demonstrates no effect on sperm DNA or male fertility [abstract]. *Neurology* 82(10 Supp):P2.233.
- De Santis M, et al. 2005. Paternal and maternal exposure to leflunomide: pregnancy and neonatal outcome. *Ann Rheum Dis* 64:1096-1097.
- Dobson R, et al. 2019. UK consensus on pregnancy in multiple sclerosis: 'Association of British Neurologists' guidelines. *Pract Neurol*. 19:106-14
- Gold R and Wolinsky JS. 2011. Pathophysiology of multiple sclerosis and the place of teriflunomide. *Acta Neurol Scand* 124(2):75-84.
- Henson LJ, et al. 2014. Updated pregnancy outcomes in patients and partners of patients in the teriflunomide clinical trial program [abstract]. *Neurology* 82(10 Supp): P4.161.
- Kieseier B, et al. 2012. Pregnancy outcomes from the teriflunomide clinical development programme: retrospective analysis of the teriflunomide clinical trial database (Poster 737). *Mult Scler*;18(Suppl 4):328.
- Losee JE and Mason AC. 2005. Deformational plagiocephaly: diagnosis, prevention, and treatment. *Clin Plastic Surg* 31;53-64
- Lu E, et al. 2013. Safety of disease-modifying drugs for multiple sclerosis in pregnancy: current challenges and future considerations for effective pharmacovigilance. *Expert Reviews* 13(3):251-61.
- O'Connor P, et al. 2011: Randomized trial of oral teriflunomide for relapsing multiple sclerosis. *N Engl J Med* 365(14):1293-1303.
- Varytė G, et al. 2021. Pregnancy and multiple sclerosis: an update. *Curr Opin Obstet Gynecol* 33(5):378-383.
- Vukusic S, et al. 2020. Pregnancy outcomes in patients with multiple sclerosis treated with teriflunomide: Clinical study data and 5 years of post-marketing experience. *Mult Scler* 26(7):829-836.
- Weber-Schoendorfer C, et al. 2017. Leflunomide – A human teratogen? A still not answered question. An evaluation of the German Embryotox pharmacovigilance database. *Reprod Toxicol* 71:101-107.

¿Preguntas? Llame al 866.626.6847 | Texto 855.999.3525 | Correo electrónico o chat en [MotherToBaby.org](https://www.MotherToBaby.org) .

Descargo de responsabilidad: las hojas informativas de MotherToBaby están destinadas a fines de información general y no deben reemplazar los consejos de su proveedor de atención médica. MotherToBaby es un servicio de la Organización sin fines de lucro de Especialistas en Información de Teratología (OTIS). Copyright de OTIS, 1 de diciembre de 2024.

## Teriflunomide

### Selected References:

- Bach V, et al. 1989. A randomized comparison between midazolam and thiopental for elective cesarean section anesthesia. III. Placental transfer and elimination in neonates. *Anesth Analg*. 68:238-42.
- Frolich MA, et al. 2006. A single dose of fentanyl and midazolam prior to Cesarean section have no adverse neonatal effects. *Can J Anaesth*. 53(1):79-85.
- Iyilikci L, et al. 2007. Sedation for endoscopic retrograde cholangiopancreatography (ERCP) in a pregnant patient. *J Anesth*. 21(1):69-71.
- Kanto J, et al. 1984. Pharmacokinetics and sedative effect of midazolam in connection with cesarean section performed under epidural analgesia. *Acta Anaesthesiol Scand* 28:116-8.
- Kelly LE, et al. 2012. Neonatal Benzodiazepines Exposure during Breastfeeding. *J Pediatr*. 161(3):448-451.
- Koitabashi T, et al. 1997. Intravenous midazolam passage into breast milk. *J Anesth*. 11:242-3.
- Nitsun M, et al. 2006. Pharmacokinetics of midazolam, propofol, and fentanyl transfer to human breast milk. *Clin Pharmacol* 79:549-57.
- Olutoye OA, et al. 2018. Food and Drug Administration warning on anesthesia and brain development: implications for obstetric and fetal surgery. *Am J Obstet* 218(1):98-102.
- Senel AC, et al. 2014. Premedication with midazolam prior to caesarean section has no neonatal adverse effects. *Braz J Anesthesiol*. 64(1):16-21.
- Shergill AK, et al. 2012. Guidelines for endoscopy in pregnant and lactating women. *Gastrointest Endosc*. 76(1):18-24.
- Swanson RJ, Leavitt MG. 1992. Fertilization and mouse embryo development in the presence of midazolam. *Anesth Analg* 75: 549-54, 1992.
- Uguz A New Safety Scoring System for the Use of Psychotropic Drugs During Lactation. *Am J Ther*. 2021 Jan-Feb 01;28(1):e118-e126. doi: 10.1097/MJT.0000000000000909. PMID: 30601177.
- Wilson CM, et al. 1987. A comparison of the early pharmacokinetics of midazolam in pregnant and nonpregnant women. *Anaesthesia*. 42:1057-62.
- Xu J, et al 2019. Early Developmental Exposure to Repetitive Long Duration of Midazolam Sedation Causes Behavioral and Synaptic Alterations in a Rodent Model of Neurodevelopment. *J Neurosurg Anesthesiol*.

31(1):151-

- Young C, et al. 2005. Potential of ketamine and midazolam, individually or in combination, to induce apoptotic neurodegeneration in the infant mouse brain. *Br J Pharmacol.* 146(2):189-97.

¿Preguntas? Llame al 866.626.6847 | Texto 855.999.3525 | Correo electrónico o chat en [MotherToBaby.org](https://www.MotherToBaby.org) .

Descargo de responsabilidad: las hojas informativas de MotherToBaby están destinadas a fines de información general y no deben reemplazar los consejos de su proveedor de atención médica. MotherToBaby es un servicio de la Organización sin fines de lucro de Especialistas en Información de Teratología (OTIS). Copyright de OTIS, 1 de diciembre de 2024.

---

## Teriflunomide

---

### Selected References:

- Holt RI, Peveler RC. 2011. Antipsychotics and hyperprolactinemia: mechanisms, consequences and management. *Clin Endocrinol (Oxf).* 74(2):141-7.
- Einarson A, Boskovic R. 2009. Use and safety of antipsychotic drugs during pregnancy. *J Psychiatr Pract.* 15(3):183-92.
- Loxitane® Product Label. Revised 2017. Available at URL: [https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2017/017525s051,017658s038,018039s024lbl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/017525s051,017658s038,018039s024lbl.pdf)
- Maguire GA. 2002. Prolactin elevation with antipsychotic medications: mechanisms of action and clinical consequences. *J Clin Psychiatry.* 63 Suppl 4:56-62.
- Parikh T, et al. 2014. Antipsychotic drugs and safety concerns for breast-feeding infants. *South Med J.* 107(11):686-8.
- Torre, DL, and Falorni, A. 2017. Pharmacological causes of hyperprolactinemia. *Therapeutics and clinical risk management.* 3(5): 929-51.

¿Preguntas? Llame al 866.626.6847 | Texto 855.999.3525 | Correo electrónico o chat en [MotherToBaby.org](https://www.MotherToBaby.org) .

Descargo de responsabilidad: las hojas informativas de MotherToBaby están destinadas a fines de información general y no deben reemplazar los consejos de su proveedor de atención médica. MotherToBaby es un servicio de la Organización sin fines de lucro de Especialistas en Información de Teratología (OTIS). Copyright de OTIS, 1 de diciembre de 2024.

## Teriflunomide

### Selected References:

- American College of Obstetricians and Gynecologists. Urinary tract infections in pregnant individuals. Clinical Consensus No. 4. *Obstet Gynecol*;142:435-45.
- Ailes EC, et al. 2018. Antibiotics dispensed to privately insured pregnant women with urinary tract infections - United States, 2014. *MMWR Morb Mortal Wkly Rep*, 67(1):18-22.
- Andersen JT et al. 2013. Trimethoprim use in early pregnancy and the risk of miscarriage: a register-based nationwide cohort study. *Epidemiol Infect*, 141:1749-1755.
- Cooper M, et al. 2014. Clinical Inquiry: how best to treat UTIs in women who breastfeed? *J Fam Pract*, 63(2):102-3.
- Crider KS, et al. 2009. Antibacterial medication use during pregnancy and risk of birth defects. *Arch Pediatr Adolesc Med*,163:978-985.
- Crowe HM, et al. 2021. Antibiotics and fecundability among female pregnancy planners: a prospective cohort study. *Hum Reprod*, 18;36(10):2761-2768.
- Czeizel AE, et al. 2001. The teratogenic risk of trimethoprim-sulfonamides: a population-based case-control study. *Reprod Toxicol*,15:637-646.
- Czeizel AE, et al. 2004. Possible association between different congenital abnormalities and use of different sulfonamides during pregnancy. *Congenital Abnormalities*, 44:79-86.
- Ford N, et al. 2014. Safety of co-trimoxazole in pregnancy: a systematic review and meta-analysis. *J Acquir Immune Defic Syndr*, 66(5): 512-521.
- Hansen C, et al. 2016. Trimethoprim-sulfonamide use during the first trimester of pregnancy and the risk of congenital anomalies. *Pharmacoepidemiol Drug Saf*, 25(2):170-8.
- Hernandez S, et al. 2000. Folic acid antagonists during pregnancy and the risk of birth defects. *N Engl J Med*, 343:1608-1614.
- Hernandez-Diaz S, et al. 2001. Neural tube defects in relation to use of folic acid antagonists during pregnancy. *Am J Epidemiol*, 153:961-968.
- Klarskov P et al. 2013. Short-acting sulfonamides near term and neonatal jaundice. *Obstet Gynecol*, 122:105-110.

- Li P, et al. 2020. Maternal exposure to sulfonamides and adverse pregnancy outcomes: A systematic review and meta-analysis. PLoS One, 15(12):e
- Molgaard-Nielsen D, Hviid A. 2012. Maternal use of antibiotics and the risk of orofacial clefts: a nationwide cohort Pharmacoepidemiol Drug Saf, 21:246-253.
- Murdia A, et al. 1978. Sulpha-trimethoprim combinations and male fertility. Lancet, 2:375-376.
- Muanda FT et al. 2018. Use of trimethoprim-sulfamethoxazole during pregnancy and risk of spontaneous abortion: a nested case control study. BJCP, 84(6):1198-1205.
- NIH-U.S. National Library of Medicine (2021). LABEL: BACTRIM DS- sulfamethoxazole and trimethoprim tablet. (nih.gov) Available at DailyMed <https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm>. Accessed November 14, 2024
- Santos F et al. 2011. Exposure to anti-infective drugs during pregnancy and the risk of small-for-gestational-age newborns: a case-control study. BJOG, 118:1374-1382.
- Wen SW, et al. 2008. Maternal exposure to folic acid antagonists and placenta-mediated adverse pregnancy outcomes. CMAJ, 179:1263-1268.
- Yang J et al. 2011. Exposure to trimethoprim/sulfamethoxazole but not other FDA category C and D anti-infectives is associated with increased risks of preterm birth and low birth weight. Int J Infect Dis, 15:e336- 341.
- Yu PA, et al. 2020. Safety of antimicrobials during pregnancy: a systematic review of antimicrobials considered for treatment and postexposure prophylaxis of p Clin Infect Dis, 70(70 Suppl 1):S37-S50.

¿Preguntas? Llame al 866.626.6847 | Texto 855.999.3525 | Correo electrónico o chat en [MotherToBaby.org](https://www.MotherToBaby.org) .

Descargo de responsabilidad: las hojas informativas de MotherToBaby están destinadas a fines de información general y no deben reemplazar los consejos de su proveedor de atención médica. MotherToBaby es un servicio de la Organización sin fines de lucro de Especialistas en Información de Teratología (OTIS). Copyright de OTIS, 1 de diciembre de 2024.

---

## Teriflunomide

---

### Selected References:

- Bauer RL, et al. 2017. Use of transdermal selegiline in pregnancy and lactation: a case report. Psychosomatics, 58(4):450-452.

- Hagell P, et al. 1998. Pregnancy in Parkinson's disease: a review of the literature and a case report. *Mov Disord*, 13(1):34-38.
- Kupsch A, Oertel WH. 1998. Selegiline, pregnancy, and Parkinson's disease. *Mov Disord*, 13(1):175-176.
- Selegiline Drug Labels. Available at [https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2021/021479s010lbl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/021479s010lbl.pdf) and <https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b891bd9f-fdb8-4862-89c5-ecdd700398a3&audience=consumer>.
- Shimazu H, et al. 1995. [Study on oral administration of FPF 1100 prior to pregnancy, pregnancy, and lactation period in rats.] *Yakuri To Chiryo*, 23(1):57-70.
- Whitaker-Azmitia PM, et al. 1994. Effects of gestational exposure to monoamine oxidase inhibitors in rats: preliminary behavioral and neurochemical studies. *Neuropsychopharmacology*, 11(2):125-132.

**¿Preguntas? Llame al 866.626.6847 | Texto 855.999.3525 | Correo electrónico o chat en [MotherToBaby.org](https://www.MotherToBaby.org) .**

---

Descargo de responsabilidad: las hojas informativas de MotherToBaby están destinadas a fines de información general y no deben reemplazar los consejos de su proveedor de atención médica. MotherToBaby es un servicio de la Organización sin fines de lucro de Especialistas en Información de Teratología (OTIS). Copyright de OTIS, 1 de diciembre de 2024.